Post

New research · Ophthalmology
Investigative ophthalmology & visual science · 5d
Randomized trialInvestigative ophthalmology & visual science · 2026

A Topographical Analysis of Visual Field Improvement in a Phase 2 Randomized Trial of Nicotinamide and Pyruvate for Open-Angle Glaucoma.

C Gustavo De Moraes, Aakriti G Shukla, George A Cioffi … Jeffrey M Liebmann
Read paper
OphthalmologyRandomized trial

Nicotinamide plus pyruvate increased odds of localized visual field improvement in glaucoma

A Topographical Analysis of Visual Field Improvement in a Phase 2 Randomized Trial of Nicotinamide and Pyruvate for Open-Angle Glaucoma.

C Gustavo De Moraes … Jeffrey M Liebmann
Investigative ophthalmology & visual science · 2026
Purpose

The purpose of this study was to characterize topographical visual field (visual field) improvement using pointwise total deviation (total deviation) slopes referenced to baseline severity, and to evaluate structure-function and cognitive associations in eyes receiving nicotinamide and pyruvate (NAM + PYR) treatment versus placebo.

Methods

This post hoc analysis used study-eye data from a phase 2 randomized trial of nicotinamide (3 g/day) plus pyruvate (3 g/day) versus placebo in open-angle glaucoma, with four baseline and four post-baseline visual field visits.

Results

treated eyes were nearly 4 times more likely to show improved vision than untreated eyes

OR 3.73 (95% CI 2.36 to 5.89)
null = 12.365.89
CI excludes the null - significant
More results

Improvement clustered along arcuate pathways and within moderate-to-deep baseline damage.

The Bayesian model estimated a 98.4% posterior probability that NAM + PYR treatment increased improving locations; retinal nerve fiber layer priors corroborated modestly but did not materially refine inference.

More results

No association was found with Montreal Cognitive Assessment scores.

“
Conclusion · 1 of 2

Topographical, slope-based endpoints reveal localized arcuate visual field improvement with nicotinamide and pyruvate that is missed by global indices and not explained by cognitive change.

Conclusion · 2 of 2

Bayesian modeling suits small early-phase neuroprotection trials, although structural priors added little over this short follow-up.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving